title: Immunoreactive somatostatin-28(1-12) is increased in Huntington's disease.
abstract: Somatostatin-28(1-12) concentrations were measured in Huntington's disease (HD) postmortem tissue using a specific radioimmunoassay. Concentrations of immunoreactive somatostatin-28(1-12) were significantly increased in the caudate and putamen but were unchanged in cortical areas A9 and A17. Since somatostatin-28(1-12) terminates with the amino acids Arg-Glu-OH, we examined whether this dodecapeptide compound might exert a neurotoxic effect. Injections of somatostatin-28(1-12) into rat striatum showed no evidence of histologic damage.
authors.forename: M F
authors.initials: MF
authors.lastname: Beal
authors.forename: R
authors.initials: R
authors.lastname: Benoit
authors.forename: E D
authors.initials: ED
authors.lastname: Bird
authors.forename: J B
authors.initials: JB
authors.lastname: Martin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D001923:Brain Chemistry; D003342:Corpus Striatum / Q000187:drug effects; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis* / Q000494:pharmacology; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000032:analysis* / Q000494:pharmacology; D053561:Somatostatin-28
chemical_list: D010446:Peptide Fragments; D013004:Somatostatin; D053561:Somatostatin-28; C037197:somatostatin 28-(1-12)